Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a combination of methylprednisolone, a corticosteroid, and thiamine (vitamin B1). Methylprednisolone acts as an anti-inflammatory and immunosuppressant by modulating multiple inflammatory pathways and immune responses. Thiamine is a vitamin essential for cellular energy metabolism and may help prevent or treat deficiency states often seen in critical illness. The combination has been used in protocols targeting severe infections such as sepsis or COVID-19 to reduce inflammation and support metabolic function. Methylprednisolone reduces immune-mediated damage by suppressing cytokines and inflammatory cells, while thiamine supports mitochondrial function to potentially improve organ function during critical illness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methylprednisolone + thiamine.